Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

AIMS: Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target‐antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Lioger, Bertrand, Edupuganti, Soujanya Ratna, Mulleman, Denis, Passot, Christophe, Desvignes, Céline, Bejan‐Angoulvant, Théodora, Thibault, Gilles, Gouilleux‐Gruart, Valérie, Mélet, Julien, Paintaud, Gilles, Ternant, David
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Pharmacokinetic Dynamic Relationships
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5510084/
https://ncbi.nlm.nih.gov/pubmed/28230269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13270
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars